ArticleVirulence2012
The ebolavirus VP24 interferon antagonist: know your enemy.
Article in Virulence, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 46 citations in OpenAlex.
- Genomic Evolution and Phylodynamics of the SpeciesPathogens (Basel, Switzerland) · 2024Review
- Ebola virus disease in children: epidemiology, pathogenesis, management, and prevention.Pediatric research · 2024Review
- Aptamers: precision tools for diagnosing and treating infectious diseases.Frontiers in cellular and infection microbiology · 2024Review
- Article
- The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections.Life (Basel, Switzerland) · 2021Review
- A biaryl sulfonamide derivative as a novel inhibitor of filovirus infection.Antiviral research · 2020Article
- Investigating the Cellular Transcriptomic Response Induced by the Makona Variant of Ebola Virus in Differentiated THP-1 Cells.Viruses · 2019Article
- Article
- Investigating Ebola virus pathogenicity using molecular dynamics.BMC genomics · 2017Article
- Novel activities by ebolavirus and marburgvirus interferon antagonists revealed using a standardized in vitro reporter system.Virology · 2017Article
- Conserved differences in protein sequence determine the human pathogenicity of Ebolaviruses.Scientific reports · 2016Article
- Ebola Virus Infection: Overview and Update on Prevention and Treatment.Infectious diseases and therapy · 2015Article
- Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks.Antimicrobial agents and chemotherapy · 2015Review
- Ebola virus disease: societal challenges and new treatments.Journal of internal medicine · 2015Review
- Assessing the contribution of interferon antagonism to the virulence of West African Ebola viruses.Nature communications · 2015Article
- Analysis of the highly diverse gene borders in Ebola virus reveals a distinct mechanism of transcriptional regulation.Journal of virology · 2014Article
- Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1.Cell host & microbe · 2014Article
- A dead-end host: is there a way out? A position piece on the ebola virus outbreak by the international union of immunology societies.Frontiers in immunology · 2014Review
- The PDB database is a rich source of alpha-helical anti-microbial peptides to combat disease causing pathogens.F1000Research · 2014Article
- DOCLASP - Docking ligands to target proteins using spatial and electrostatic congruence extracted from a known holoenzyme and applying simple geometrical transformations.F1000Research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Suppression during the early phases of the immune system often correlates directly with a fatal outcome for the host. The ebolaviruses, some of the most lethal viruses known, appear to cripple initial stages of the host defense network via multiple distinct paths. Two of the eight viral proteins are critical for immunosuppression. One of these proteins is VP35, which binds double-stranded RNA and antagonizes several antiviral signaling pathways. The other protein is VP24, which binds transporter molecules to prevent STAT1 translocation. A more recent discovery is that VP24 also binds STAT1 directly, suggesting that VP24 may operate in at least two separate branches of the interferon pathway. New crystal structures of VP24 derived from pathogenic and nonpathogenic ebolaviruses reveal its novel, pyramidal fold, upon which can be mapped sites required for virulence and for STAT1 binding. These structures of VP24, and new information about its direct binding to STAT1, provide avenues by which we may explore its many roles in the viral life cycle, and reasons for differences in pathogenesis among the ebolaviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.